Publication of evidence review

RNS Number : 9219V

Deltex Medical Group PLC

19 December 2013

 



Deltex Medical Group plc

("Deltex Medical" or "the Company")

New report on intra-operative fluid management ("IOFM") technologies' evidence bases: update on NHS plans to implement IOFM

19 December 2013 - Deltex Medical Group plc, the global leader in oesophageal Doppler monitoring ("ODM"), today provides an update on various NHS related activities.

CardioQ-ODM performs strongly in IOFM evidence review

The Company welcomes publication of a new NHS commissioned evidence review of IOFM technologies. The report was commissioned by the Kent, Surrey, Sussex Academic Health Science Network ('KSS AHSN') from Cedar Healthcare Technology Research Centre ('Cedar') as part of Cedar's contract with the National Institute of Health and Care Excellence ('NICE') for evidence assessment. KSS is the leading AHSN on IOFM adoption in the NHS.

The report lists and summarises published randomised controlled trials of each of the different IOFM technologies available to the NHS. Deltex Medical's CardioQ-ODM has the highest number of such trials, the most trials showing reduced complications and the most trials showing reduced length of hospital stay. The report can be downloaded at http://www.cedar.wales.nhs.uk/page/71545.

IOFM receives its own NHS code

In a separate development NHS England has established a new Office of Population Censuses and Surveys Classification of Interventions and Procedures ('OPCS') code for IOFM, Y73.6, effective from 1 April 2014. This is the first time that IOFM will be separately identified within the NHS coding system and is expected to make it substantially easier for NHS organisations to monitor and audit IOFM adoption and, in time, to establish which technologies are associated with the best outcomes for patients.

NHS Innovation Health and Wealth report refresh scheduled for January 2014

The Company has identified a number of weaknesses in the implementation plans put in place following the 2011 NHS Chief Executive's Innovation Health and Wealth (IHW) report which identified ODM as one of six high impact innovations to be adopted nationally by the NHS at pace and scale. The Company is in dialogue with the NHS concerning these weaknesses as part of an ongoing exercise by the NHS to 'refresh' IHW. The Company has been informed that the IHW refresh exercise is now likely to run into January 2014 and that the outcome with regard to the Company's recommendations and proposals is unlikely to be finalised until after the output of the refresh exercise is known. As a consequence any decision on a potential central NHS stocking order of CardioQ-ODM equipment will be deferred into the Company's next financial year.

Ewan Phillips, Chief Executive of Deltex Medical, commented:

"We are pleased that the NHS has now published an independent report on the evidence supporting the various IOFM technologies, in which CardioQ-ODM has performed strongly, and are encouraged that this, together with the forthcoming OPCS code for IOFM, has come out in advance of the update to Innovation Health and Wealth. The clinical and economic cases for deep and broad adoption of ODM are as compelling as ever, as is the need for the NHS to become capable of adopting innovative medical technologies systematically at pace and scale."

For further information, please contact:-

Deltex Medical Group plc	01243 774 837 [e-mail]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Paul Mitchell, Finance Director
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie
Financial Public Relations
Newgate Threadneedle	020 7653 9850
Graham Herring
Caroline Evans-Jones
Heather Armstrong

Notes for Editors

Deltex Medical manufactures and markets CardioQ-ODMÔ Oesophageal Doppler Monitoring ('ODM') systems. ODM is the only therapy to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

The CardioQ-ODM has two distinct established clinical applications: firstly, to guide fluid management during surgery and secondly, to monitor cardiac output in critical care settings.

Surgical market

In March 2011 the National Institute for Health & Clinical Excellence ('NICE') recommended that CardioQ-ODM be considered for use in patients undergoing major and high risk surgery and in high risk patients undergoing intermediate risk surgery. NICE estimated the applicable number of such patients in the NHS in England alone to be over 800,000 each year. CardioQ-ODM has been shown to be effective in both elective and emergency surgery and with both general and regional anaesthetics. This recommendation was specific to CardioQ-ODM and was based on the robust evidence base that supports its use.

Subsequent to the NICE guidance, the NHS in England announced its selection of ODM as a high impact innovation to be rolled out across the system fully, at pace and scale with significant financial penalties starting in the NHS 2013/14 financial year ending 31 March 2014.

The NICE evaluation and recommendation confirms that the potential global market for CardioQ-ODM in surgery includes tens of millions of patients, even if confined to developed health economies: the most conservative estimate of the potential value of the market opportunity Deltex Medical has created is in excess of £1 billion per annum. The Company's core focus is on building market leading positions in this surgical market, both geographically and by type of surgery.

Critical care market

In critical care settings, well-equipped hospitals will often have more than one cardiac output monitoring technology available. In this environment, ODM's strengths are that it is quick to set up, easy to use, safe, low cost and the ideal technology for a patient in crisis requiring rapid or frequent intervention. The potential market for cardiac output monitoring in critical care is a fraction of the size of that for intra-operative fluid management.

Through the 2012 launch of the CardioQ-ODM+, Deltex Medical has added the Pulse Pressure Waveform Analysis ('PPWA') approach to monitoring cardiac output to ODM functionality. Doing this has improved Deltex Medical's offer for monitoring applications as well as providing doctors and nurses with a choice of clinical strategies appropriate to individual patients in different clinical settings.

Company goal

Our goal is to make oesophageal Doppler monitoring (ODM) a standard of care for patients in both these markets. We believe that, in most modern health systems, it is essential to have a robust evidence base of both clinical benefit and cost effectiveness in order to achieve system-wide adoption of a new medical technology. Deltex Medical is one of the very first medical technology companies to have completed the investment necessary to build such an evidence base: as a result, use of ODM during surgery has the proven potential to deliver both clinical and economic benefits that are material at each of patient, hospital and system level.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide and there are already over 2,800 CardioQ-ODM systems in use in hospitals worldwide. Distribution arrangements are in place in over 30 countries.

 

END

 

 

MSCGGGQCPUPWGMR